Current and historical daily PE Ratio for INTS (
Intensity Therapeutics Inc
) from 2023 to Jun 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Intensity Therapeutics stock (INTS) PE ratio as of Jun 19 2024 is 0.
More Details
Intensity Therapeutics Inc (INTS) PE Ratio (TTM) Chart
Intensity Therapeutics Inc (INTS) PE Ratio (TTM) Historical Data
View and export this data going back to 2023. Start your Free Trial
Total 245
- 1
- 2
- 3
Intensity Therapeutics PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-19 | At Loss | 2024-04-16 | At Loss |
2024-06-18 | At Loss | 2024-04-15 | At Loss |
2024-06-17 | At Loss | 2024-04-12 | At Loss |
2024-06-14 | At Loss | 2024-04-11 | At Loss |
2024-06-13 | At Loss | 2024-04-10 | At Loss |
2024-06-12 | At Loss | 2024-04-09 | At Loss |
2024-06-11 | At Loss | 2024-04-08 | At Loss |
2024-06-10 | At Loss | 2024-04-05 | At Loss |
2024-06-07 | At Loss | 2024-04-04 | At Loss |
2024-06-06 | At Loss | 2024-04-03 | At Loss |
2024-06-05 | At Loss | 2024-04-02 | At Loss |
2024-06-04 | At Loss | 2024-04-01 | At Loss |
2024-06-03 | At Loss | 2024-03-28 | At Loss |
2024-05-31 | At Loss | 2024-03-27 | At Loss |
2024-05-30 | At Loss | 2024-03-26 | At Loss |
2024-05-29 | At Loss | 2024-03-25 | At Loss |
2024-05-28 | At Loss | 2024-03-22 | At Loss |
2024-05-24 | At Loss | 2024-03-21 | At Loss |
2024-05-23 | At Loss | 2024-03-20 | At Loss |
2024-05-22 | At Loss | 2024-03-19 | At Loss |
2024-05-21 | At Loss | 2024-03-18 | At Loss |
2024-05-20 | At Loss | 2024-03-15 | At Loss |
2024-05-17 | At Loss | 2024-03-14 | At Loss |
2024-05-16 | At Loss | 2024-03-13 | At Loss |
2024-05-15 | At Loss | 2024-03-12 | At Loss |
2024-05-14 | At Loss | 2024-03-11 | At Loss |
2024-05-13 | At Loss | 2024-03-08 | At Loss |
2024-05-10 | At Loss | 2024-03-07 | At Loss |
2024-05-09 | At Loss | 2024-03-06 | At Loss |
2024-05-08 | At Loss | 2024-03-05 | At Loss |
2024-05-07 | At Loss | 2024-03-04 | At Loss |
2024-05-06 | At Loss | 2024-03-01 | At Loss |
2024-05-03 | At Loss | 2024-02-29 | At Loss |
2024-05-02 | At Loss | 2024-02-28 | At Loss |
2024-05-01 | At Loss | 2024-02-27 | At Loss |
2024-04-30 | At Loss | 2024-02-26 | At Loss |
2024-04-29 | At Loss | 2024-02-23 | At Loss |
2024-04-26 | At Loss | 2024-02-22 | At Loss |
2024-04-25 | At Loss | 2024-02-21 | At Loss |
2024-04-24 | At Loss | 2024-02-20 | At Loss |
2024-04-23 | At Loss | 2024-02-16 | At Loss |
2024-04-22 | At Loss | 2024-02-15 | At Loss |
2024-04-19 | At Loss | 2024-02-14 | At Loss |
2024-04-18 | At Loss | 2024-02-13 | At Loss |
2024-04-17 | At Loss | 2024-02-12 | At Loss |
Intensity Therapeutics Inc (INTS) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
Intensity Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US45828J1034
Description
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.